Menu
GeneBe

rs35350960

Variant summary

Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM5BP4_StrongBS1_SupportingBS2

The NM_000463.3(UGT1A1):c.686C>A(p.Pro229Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000476 in 1,614,172 control chromosomes in the GnomAD database, including 15 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity,other (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P229L) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.00083 ( 3 hom., cov: 33)
Exomes 𝑓: 0.00044 ( 12 hom. )

Consequence

UGT1A1
NM_000463.3 missense

Scores

2
15

Clinical Significance

Conflicting classifications of pathogenicity; other criteria provided, conflicting classifications P:4U:3B:1O:2

Conservation

PhyloP100: 0.857
Variant links:
Genes affected
UGT1A1 (HGNC:12530): (UDP glucuronosyltransferase family 1 member A1) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008]
UGT1A6 (HGNC:12538): (UDP glucuronosyltransferase family 1 member A6) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenolic and planar compounds. Alternative splicing in the unique 5' end of this gene results in two transcript variants. [provided by RefSeq, Jul 2008]
UGT1A4 (HGNC:12536): (UDP glucuronosyltransferase family 1 member A4) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. This enzyme has some glucuronidase activity towards bilirubin, although is is more active on amines, steroids, and sapogenins. [provided by RefSeq, Jul 2008]
UGT1A10 (HGNC:12531): (UDP glucuronosyltransferase family 1 member A10) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has glucuronidase activity on mycophenolic acid, coumarins, and quinolines. [provided by RefSeq, Jul 2008]
UGT1A8 (HGNC:12540): (UDP glucuronosyltransferase family 1 member A8) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has glucuronidase activity with many substrates including coumarins, phenols, anthraquinones, flavones, and some opioids. [provided by RefSeq, Jul 2008]
UGT1A7 (HGNC:12539): (UDP glucuronosyltransferase family 1 member A7) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has moderate glucuronidase activity with phenols. [provided by RefSeq, Jul 2008]
UGT1A5 (HGNC:12537): (UDP glucuronosyltransferase family 1 member A5) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. [provided by RefSeq, Jul 2008]
UGT1A3 (HGNC:12535): (UDP glucuronosyltransferase family 1 member A3) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. Substrates of this enzyme include estrone, 2-hydroxyestrone, and metabolites of benzo alpha-pyrene. [provided by RefSeq, Jul 2008]
UGT1A9 (HGNC:12541): (UDP glucuronosyltransferase family 1 member A9) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenols. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -7 ACMG points.

PM5
Other missense variant is known to change same aminoacid residue: Variant chr2-233760973-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 1409267.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=2, Likely_pathogenic=1}.
BP4
Computational evidence support a benign effect (MetaRNN=0.008823067).
BS1
Variant frequency is greater than expected in population eas. gnomad4 allele frequency = 0.000834 (127/152280) while in subpopulation EAS AF= 0.0181 (94/5180). AF 95% confidence interval is 0.0152. There are 3 homozygotes in gnomad4. There are 44 alleles in male gnomad4 subpopulation. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd at 3 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
UGT1A1NM_000463.3 linkuse as main transcriptc.686C>A p.Pro229Gln missense_variant 1/5 ENST00000305208.10
UGT1A6NM_001072.4 linkuse as main transcriptc.862-6061C>A intron_variant ENST00000305139.11
UGT1A4NM_007120.3 linkuse as main transcriptc.868-6061C>A intron_variant ENST00000373409.8
UGT1A10NM_019075.4 linkuse as main transcriptc.856-6061C>A intron_variant ENST00000344644.10
UGT1A8NM_019076.5 linkuse as main transcriptc.856-6061C>A intron_variant ENST00000373450.5
UGT1A7NM_019077.3 linkuse as main transcriptc.856-6061C>A intron_variant ENST00000373426.4
UGT1A5NM_019078.2 linkuse as main transcriptc.868-6061C>A intron_variant ENST00000373414.4
UGT1A3NM_019093.4 linkuse as main transcriptc.868-6061C>A intron_variant ENST00000482026.6
UGT1A9NM_021027.3 linkuse as main transcriptc.856-6061C>A intron_variant ENST00000354728.5

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
UGT1A1ENST00000305208.10 linkuse as main transcriptc.686C>A p.Pro229Gln missense_variant 1/51 NM_000463.3 P1P22309-1
UGT1A6ENST00000305139.11 linkuse as main transcriptc.862-6061C>A intron_variant 1 NM_001072.4 P1P19224-1
UGT1A10ENST00000344644.10 linkuse as main transcriptc.856-6061C>A intron_variant 1 NM_019075.4 P1Q9HAW8-1
UGT1A9ENST00000354728.5 linkuse as main transcriptc.856-6061C>A intron_variant 1 NM_021027.3 P1O60656-1
UGT1A4ENST00000373409.8 linkuse as main transcriptc.868-6061C>A intron_variant 1 NM_007120.3 P1P22310-1
UGT1A5ENST00000373414.4 linkuse as main transcriptc.868-6061C>A intron_variant 1 NM_019078.2 P1P35504-1
UGT1A7ENST00000373426.4 linkuse as main transcriptc.856-6061C>A intron_variant 1 NM_019077.3 P1Q9HAW7-1
UGT1A8ENST00000373450.5 linkuse as main transcriptc.856-6061C>A intron_variant 1 NM_019076.5 P1Q9HAW9-1
UGT1A3ENST00000482026.6 linkuse as main transcriptc.868-6061C>A intron_variant 1 NM_019093.4 P1P35503-1

Frequencies

GnomAD3 genomes
AF:
0.000828
AC:
126
AN:
152164
Hom.:
3
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00183
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.0179
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.000956
GnomAD3 exomes
AF:
0.00148
AC:
372
AN:
251388
Hom.:
3
AF XY:
0.00143
AC XY:
194
AN XY:
135886
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.0000867
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0193
Gnomad SAS exome
AF:
0.000294
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000880
Gnomad OTH exome
AF:
0.000489
GnomAD4 exome
AF:
0.000439
AC:
642
AN:
1461892
Hom.:
12
Cov.:
34
AF XY:
0.000468
AC XY:
340
AN XY:
727246
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000894
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0119
Gnomad4 SAS exome
AF:
0.000255
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000540
Gnomad4 OTH exome
AF:
0.00227
GnomAD4 genome
AF:
0.000834
AC:
127
AN:
152280
Hom.:
3
Cov.:
33
AF XY:
0.000591
AC XY:
44
AN XY:
74472
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00183
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.0181
Gnomad4 SAS
AF:
0.000208
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.000946
Alfa
AF:
0.000911
Hom.:
5
Bravo
AF:
0.000937
ExAC
AF:
0.00137
AC:
166
Asia WGS
AF:
0.00895
AC:
31
AN:
3478
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Conflicting classifications of pathogenicity; other
Submissions summary: Pathogenic:4Uncertain:3Benign:1Other:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Pathogenic:2Uncertain:1Other:1
Uncertain significance, criteria provided, single submitterclinical testingInvitaeJan 18, 2024This sequence change replaces proline, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 229 of the UGT1A1 protein (p.Pro229Gln). This variant is present in population databases (rs35350960, gnomAD 2.0%), and has an allele count higher than expected for a pathogenic variant. This variant has been observed in individual(s) with Gilbert disease (PMID: 7715297, 8528206, 14616765). This variant is frequently observed to be in cis with the c.-41_-40dup (aka UGT1A1*28 or (TA)7) variant (PMID: 11316168, 19325249, 15304120) This variant is also known as UGT1A1*27. ClinVar contains an entry for this variant (Variation ID: 12274). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt UGT1A1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects UGT1A1 function (PMID: 8528206, 18004206). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesOct 26, 2023The UGT1A1 c.686C>A, p.Pro229Gln variant (rs35350960; ClinVar Variation ID: 12274), also known as the UGT1A1*27 allele (Mackenzie 1997), is reported in the literature in individuals of East Asian descent affected with Gilbert syndrome, almost always with one or two copies of the pathogenic-mild UGT1A1 *28 promoter variant (Huang 2000, Koiwai 1995, Maruo 2003, Sai 2004, Sun 2017). Functional analyses of the p.Pro229Gln variant protein showed markedly reduced enzyme activity (Koiwai 1995, Udomuksorn 2007). Individuals heterozygous for the UGT1A1*27 allele may also be at increased risk for drug toxicity when treated with irinotecan (Ando 2000, Teh 2012). This variant is found predominantly in the East Asian population with an overall allele frequency of 1.9% (389/19954 alleles, including three homozygotes) in the Genome Aggregation Database. The proline at codon 229 is highly conserved, but computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.32). Based on available information, this variant is considered to be mildly pathogenic for Gilbert syndrome with reduced penetrance. References: Ando Y et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000 60:6921-6926. PMID: 11156391 Huang CS et al. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics. 2000 10:539-544. PMID: 10975608 Kaniwa N et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos. 2005 33:458-465. PMID: 15572581 Koiwai O et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet. 1995 4:1183-1186. PMID: 8528206 Mackenzie PI et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics. 1997 7:255-269. PMID: 9295054 Maruo Y et al. Co-occurrence of three different mutations in the bilirubin UDP-glucuronosyltransferase gene in a Chinese family with Crigler-Najjar syndrome type I and Gilbert's syndrome. Clin Genet. 2003 64:420-423. PMID: 14616765 Sai K et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004 75:501-515. PMID: 15179405 Sun L et al. Differences in UGT1A1 gene mutations and pathological liver changes between Chinese patients with Gilbert syndrome and Crigler-Najjar syndrome type II. Medicine (Baltimore). 2017 96:e8620. PMID: 29137095 Teh LK et al. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia. Indian J Med Res. 2012 136:249-259. PMID: 22960892 Udomuksorn W et al. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 17:1017-1029. PMID: 18004206 -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicJul 09, 2020- -
other, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Sep 17, 2018- Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles).
Gilbert syndrome Pathogenic:1Other:1
Affects, no assertion criteria providedliterature onlyOMIMDec 01, 2007- -
Pathogenic, no assertion criteria providedcase-controlDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing You An Hospital, Capital Medical UniversityMay 01, 2019- -
not specified Uncertain:1Benign:1
Benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoFeb 08, 2013- -
Uncertain significance, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineJun 19, 2020The p.Pro229Gln variant in UGT1A1 has been reported in the heterogygous and compound heterozygous state in numerous individuals with Gilbert syndrome or Crigler-Najjar syndrome type II , however, most of them were also homozygous for other pathogenic variants in the gene. This variant has also been reported in ClinVar (Variation ID 12274). It has been identified in 1.9% (389/19954) of East Asian chromosomes by gnomAD (https://gnomad.broadinstitute.org/). Computational prediction tools and conservation analysis suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In vitro functional studies provide some evidence that this variant impacts protein function (Gagne 2002 PMID: 12181437, Udomuksorn 2007 PMID: 18004206); however, these types of assays may not accurately represent biological function. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS3_Supporting, BS1_Supporting, BP4. -
Crigler-Najjar syndrome, type II Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMDec 01, 2007- -
UGT1A1-related condition Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesFeb 08, 2024The UGT1A1 c.686C>A variant is predicted to result in the amino acid substitution p.Pro229Gln. The minor allele frequency of this variant is over 1% in the East Asian sub-population, including 3 homozygotes, indicating this variant may be too common to be a primary cause of a Mendelian disease. However, an in vitro study indicated this variant caused a reduction in the activity of bilirubin UDP-glucuronosyltransferase (UGT) (Koiwai et al. 1995. PubMed ID: 8528206). The contribution of this variant to disease remains under debate (Kaniwa et al. 2005. PubMed ID: 15572581; Zhang et al. 2007. PubMed ID: 17060921; Wisnumurti et al. 2018. PubMed ID: 29607327), and classifications for this variant from outside laboratories range from benign to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/12274/). Therefore, we classify c.686C>A (p.Pro229Gln) as a variant of uncertain significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.19
BayesDel_addAF
Benign
-0.28
T
BayesDel_noAF
Benign
-0.16
Cadd
Benign
14
Dann
Benign
0.97
DEOGEN2
Benign
0.23
T;.
Eigen
Benign
-0.39
Eigen_PC
Benign
-0.45
FATHMM_MKL
Benign
0.16
N
LIST_S2
Benign
0.63
T;T
MetaRNN
Benign
0.0088
T;T
MetaSVM
Benign
-0.80
T
MutationAssessor
Uncertain
2.2
M;M
MutationTaster
Benign
0.68
N;N;N;N;N;N;N;N;N;N;N;N;N
PROVEAN
Benign
-2.1
N;D
REVEL
Uncertain
0.32
Sift
Benign
0.16
T;T
Sift4G
Benign
0.53
T;T
Polyphen
0.60
P;.
Vest4
0.34
MVP
0.62
MPC
0.45
ClinPred
0.11
T
GERP RS
4.9
Varity_R
0.12
gMVP
0.45

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs35350960; hg19: chr2-234669619; COSMIC: COSV59386733; COSMIC: COSV59386733; API